Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 1;8(2):e002253. doi: 10.1136/rmdopen-2022-002253

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Spydergrams of SF-36v2 domains from baseline to (A) week 16 and (B) week 48. Spydergrams of SF-36v2 domain scores from baseline to (A) week 16 (data cut-off 19 December 2019; data snapshot 29 January 2020) and (B) week 48 versus age-matched and sex-matched norms, in patients with AS receiving tofacitinib 5 mg twice daily or placebo→tofacitinib 5 mg twice daily.^† Spydergrams were based on sample means generated using domain 0–100 scores. US age-sex norms were matched to the protocol population. Spydergrams are for illustrative purposes only. **p<0.01, ***p<0.001 for tofacitinib 5 mg twice daily versus placebo (week 16) without adjustment for multiple comparisons. P values at week 16 were generated using ANCOVA, including data at week 16 for comparisons with placebo based on LS mean changes from baseline in domain norm-based scores to week 16. ^†Patients receiving placebo advanced to tofacitinib 5 mg twice daily at week 16. ANCOVA, analysis of covariance; AS, ankylosing spondylitis; BID, twice daily; LS, least squares; SF-36v2, Short Form-36 Health Survey Version 2.